FIRST SYMPTOMS AND THEIR AGE OF ONSET IN MACULAR TELANGIECTASIA TYPE 2Heeren, Tjebo F. C. MD; Holz, Frank G. MD; Issa, Peter Charbel MDRetina: May 2014 - Volume 34 - Issue 5 - p 916–919 doi: 10.1097/IAE.0000000000000082 Original Study Abstract In Brief Author Information Abstract Purpose: To investigate the first symptoms and their age of onset in a large cohort of patients with macular telangiectasia type 2. Methods: Patients with the characteristic findings of macular telangiectasia type 2 were interviewed. Data collection also included a chart review to determine the delay of the correct diagnosis and visual function 10 years after the onset of first symptoms. Results: Of 91 patients, 72 (79%) reported impaired reading ability as their first symptom, followed by metamorphopsia in 12%. The age of onset was most frequent (76%) in the sixth or seventh decade of life (50–69 years), and 58% of the patients were symptomatic before the age of 60 years. The median delay between first symptoms and the diagnosis of macular telangiectasia type 2 before the year 2005 was 7 years and has decreased to 1 year thereafter. Ten years after the onset of first symptoms, distance visual acuity of the better eye was ≥20/25 in 35% and ≤20/50 in 17%. Conclusion: Impaired reading ability was the most common initial visual disturbance of patients with macular telangiectasia type 2, starting generally between the age of 50 and 70 years. Knowledge of the presenting symptoms of macular telangiectasia type 2 together with recently identified characteristic morphologic alterations on retinal imaging will likely lead to earlier accurate diagnosis of this disease entity. In Brief The most common first symptom of patients with macular telangiectasia type 2 is impaired reading ability (79%), followed by metamorphopsia (12%). Approximately three of four patients experience first symptoms in their sixth or seventh decade. Visual acuity may remain well preserved even 10 years after the onset of symptoms. Author Information Department of Ophthalmology, University of Bonn, Bonn, Germany. Reprint requests: Peter Charbel Issa, MD, Department of Ophthalmology, University of Bonn, Ernst-Abbe Street 2, 53127 Bonn, Germany; e-mail: email@example.com Supported by ProRetina, Lowy Medical Research Institute. None of the authors have any financial/conflicting interests to disclose. © 2014 by Ophthalmic Communications Society, Inc.